TABLE 1.

PG545 inhibits HSV-2 plaque-forming activity and inactivates infectivity of free virus particles

HSV-2 strain or clinical isolate	IC50 (μg/ml) as determined by plaque assay		Virus-inactivation activitya at indicated concn (μg/ml) of agent
	PG545	Acyclovir	PG545			Acyclovir
			100	20	4	100	20	4
333	0.8	7.3	0.0	0.0	0.0	103.5	113.8	100.0
DE06-3942b	0.4	>100	0.0	0.0	0.0	85.3	100	88
DE07-6820b	0.5	>100	0.0	0.0	2.8	108.7	104.9	102.9
VI03-1678c	0.6	3.6	0.0	0.0	0.0	113.4	104.9	108.5
90-036	0.4	3.0	0.0	0.0	52.2	99.4	108.5	100
90-306	0.4	2.3	0.0	0.0	73.6	99.4	103.2	93.6

^aVirus-inactivating activity is expressed as the percentage of residual infectivity found with PG545- or acyclovir-treated virus relative to that of the mock-treated virus control.

^bClinical isolate of HSV-2 resistant to acyclovir.

^cClinical isolate of HSV-2 from routine diagnostics.